We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Treated Fabric with Antiviral and Antibacterial Properties Rapidly Destroys 99.99% of Coronavirus

By HospiMedica International staff writers
Posted on 09 Jun 2020
A new textile technology has proven effective against SARS-CoV-2 in the laboratory with tests demonstrating that the treated fabric achieved a 99.99% reduction of the virus.

The HeiQ Viroblock NPJ03, developed by textile innovator HeiQ (Zurich, Switzerland) is a textile treatment for industrial use, designed to provide textiles with antiviral and antibacterial properties. More...
The combination of silver antimicrobial technology and vesicle technology rapidly destroy enveloped viruses including coronaviruses. It has previously been tested against coronavirus 229E, another strain of virus in the coronavirus family.

The latest research project involved a disinfection test protocol that simulated the real-life interaction of small aerosol droplets contaminating clothing. A known concentration of SARS-CoV-2 virus was contacted with the sample fabric for 30 minutes, followed by measurement of remaining infectious SARS-CoV-2 viruses. The fabric sample treated with HeiQ Viroblock NPJ03 had no infective viruses left after 30 minutes. The result indicated a SARS-CoV-2 virus reduction of 99.99% relative to the inoculum control.

"The confirmation of antiviral activity of HeiQ Viroblock against SARS-CoV-2 is an important milestone. This data forms part of our ongoing efforts to help provide textiles with greater levels of protection against viruses and contribute to efforts towards mitigation of the global pandemic," said Carlo Centonze, Swiss co-founder and Chief Executive Officer of HeiQ Group.

Related Links:
HeiQ


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
Surgical Headlight
IsoTorch
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.